EMEA Organization
~166 FTEs & $95 MM OPEX

August, 2026
EMEA: 3.5% ($1.3B)
Rest of Company: 96.5% ($35.6B)
All figures reflect preliminary thinking & assumptions; to be confirmed
EMEA Organization
~166 FTEs & $95 MM OPEX
Global Clin Ops and Tech Ops
~51 FTEs & ~$25 MM annual OPEX
EMEA commercialisation engine
~ 115 FTEs & ~$70 MM annual OPEX
Continued commercialization options improve EBITDA
All figures reflect preliminary thinking & assumptions; to be confirmed

All figures reflect preliminary thinking & assumptions; to be confirmed
1. Initial Estimate to be confirmed depending on severance package, # impacted employees, etc
Key risks of exit include cultural hit, corporate reputation, loss of KOL relationships, clinical trial recruitment impact, ceding first-mover advantage to competitors
Next Steps: Review EMEA team recommendation & assumptions, refine analysis, develop implementation and communication plan
Represents cumulative break-even
Germany
UK
France
Italy
Spain
Germany
UK
France
Italy
SpainG&A costs have not been allocated to the individual countries; All other infrastructure costs are included
1. Prices represent direct pricing. (team is proposing import model initially)
Potential savings of ~140m to ~180m
1. All figures reflect preliminary thinking & assumptions; to be confirmed
Note: COGS includes royalties expenses
Commercial -59, Medical -25, G&A -15, QA -7, Others -9
Commercial +7, QA + Supply +3 G&A +5
Commercial +21, Medical +3, G&A +1
1. All figures reflect preliminary thinking & assumptions; to be confirmed